In the third quarter, Baillie Gifford & Co. reduced its stake in Procter & Gamble by 2.8%, selling 26,105 shares to end the period with 919,290 shares valued at $141.25 million per the latest 13F filing. This adjustment contrasts with significant increases by other institutions: Brighton Jones LLC boosted its position by 51.5%, acquiring 13,617 shares to hold 40,068 shares worth $6.72 million; Sivia Capital Partners lifted its stake by 19.8%, adding 1,016 shares to reach 6,144 shares valued at $979,000; Auxano Advisors expanded by 10.8%, purchasing 714 shares to hold 7,315 shares worth $1.17 million; and Perigon Wealth Management increased by 1.1%, adding 717 shares to reach 67,749 shares valued at $10.79 million. Institutional investors now control approximately 65.8% of Procter & Gamble’s shares, underscoring the importance of these portfolio shifts for market liquidity and sentiment.

A total of twenty-one analysts have issued recommendations on Procter & Gamble, with fourteen maintaining Buy ratings and seven assigning Hold ratings. Barclays reiterated its favorable stance with a $155 price objective, TD Cowen upheld a Buy rating in early January, while Morgan Stanley and DBS Bank set targets of $175 and affirmed a Buy recommendation. Raymond James Financial, however, adjusted its target down from $185 to $175, continuing to rate the stock as Outperform. The consensus Moderate Buy rating reflects an average price target near $167.20, suggesting upside potential of roughly 5% to 7% from current consensus valuation, contingent on execution against guidance and margin pressures.

In late October, Chief Accounting Officer Matthew W. Janzaruk sold 725 shares of Procter & Gamble, generating proceeds of $108,438. Following this transaction, his holdings declined by 42.6% to 979 shares, now valued at approximately $146,429. The sale was disclosed in an SEC filing and represents a rare instance of insider divestment in a company where insiders collectively own just 0.20% of outstanding shares. While such activity often attracts investor scrutiny, this trade aligns with broader corporate planning for personal liquidity rather than a signal of operational concerns.

For the fiscal second quarter ending December 31, Procter & Gamble reported earnings per share of $1.88, exceeding consensus estimates by $0.02, with revenue of $22.21 billion, slightly below the $22.36 billion forecast. Net margin stood at 19.3% and return on equity was 32.1%, while organic sales growth of 1.5% reflected stable pricing offsetting modest volume declines. The company reiterated full-year EPS guidance of $6.83 to $7.09, implying mid-single-digit growth. On the capital return front, P&G declared a quarterly dividend of $1.0568 per share, translating to an annualized yield of 2.8% and a payout ratio of approximately 63%, reinforcing its commitment to consistent distributions despite broader market volatility.